Lombardo, R.; Ruponen, M.; Rautio, J.; Ghelardini, C.; Di Cesare Mannelli, L.; Calosi, L.; Bani, D.; Lampinen, R.; Kanninen, K.M.; Koivisto, A.M.;
et al. Development of Lyophilised Eudragit® Retard Nanoparticles for the Sustained Release of Clozapine via Intranasal Administration. Pharmaceutics 2023, 15, 1554.
https://doi.org/10.3390/pharmaceutics15051554
AMA Style
Lombardo R, Ruponen M, Rautio J, Ghelardini C, Di Cesare Mannelli L, Calosi L, Bani D, Lampinen R, Kanninen KM, Koivisto AM,
et al. Development of Lyophilised Eudragit® Retard Nanoparticles for the Sustained Release of Clozapine via Intranasal Administration. Pharmaceutics. 2023; 15(5):1554.
https://doi.org/10.3390/pharmaceutics15051554
Chicago/Turabian Style
Lombardo, Rosamaria, Marika Ruponen, Jarkko Rautio, Carla Ghelardini, Lorenzo Di Cesare Mannelli, Laura Calosi, Daniele Bani, Riikka Lampinen, Katja M. Kanninen, Anne M. Koivisto,
and et al. 2023. "Development of Lyophilised Eudragit® Retard Nanoparticles for the Sustained Release of Clozapine via Intranasal Administration" Pharmaceutics 15, no. 5: 1554.
https://doi.org/10.3390/pharmaceutics15051554
APA Style
Lombardo, R., Ruponen, M., Rautio, J., Ghelardini, C., Di Cesare Mannelli, L., Calosi, L., Bani, D., Lampinen, R., Kanninen, K. M., Koivisto, A. M., Penttilä, E., Löppönen, H., & Pignatello, R.
(2023). Development of Lyophilised Eudragit® Retard Nanoparticles for the Sustained Release of Clozapine via Intranasal Administration. Pharmaceutics, 15(5), 1554.
https://doi.org/10.3390/pharmaceutics15051554
